Medical technology company, Jan Medical, announced today that it has secured $7.5 million in Series C funding from Brainlab, Inc., which will go toward ongoing clinical trials and FDA approval of its diagnostic tool designed to quickly detect abnormal neurological conditions.
The non-invasive device, called BrainPulse, could be used to identify concussion and stroke in particular. The device works by capturing a physiological signal that uses heartbeats to measure vasculature and brain tissue conditions. It consists of a headset, data collector and computer.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
BrainPulse has already been shown to improve the way concussions are detected and observed in athletes in a clinical trial at Stanford University. The device requires only 45 heartbeats to produce a file for analysis, and a typical session, carried out by a nurse in the neuro critical care unit or emergency department, takes only three minutes.
The data retrieved from BrainPulse ideally would provide researchers with valuable information to develop new therapies. The Series C funding will help Jan Medical get closer to preparation for a market launch.
Photo: Screenshot via Jan Medical
